Sign In
Buy JAZZ
$252.86
-5.52 (-2.14%)
At Close: Jul 31, 2026
Aristotle Global Equity Advisory Q2 2026 Portfolio Review
01:20am, Thursday, 30'th Jul 2026
For the second quarter of 2026, Aristotle Capital's Global Equity WM Composite posted a total return of 6.92% pure gross of fees (6.40% net of fees), underperforming the MSCI ACWI Index, which returne
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
10:41am, Tuesday, 28'th Jul 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
11:03am, Monday, 27'th Jul 2026
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is JAZZ Still the Best Cannabis Stock After Federal Rescheduling?
09:56am, Friday, 24'th Jul 2026
Jazz Pharmaceuticals pairs its FDA-approved CBD blockbuster with a diversified drug portfolio, offering medical cannabis exposure despite ongoing pipeline risks.
These major drug stocks rally after Trump's zero tariff announcement
06:31am, Wednesday, 22'nd Jul 2026
President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.
Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Tuesday, 21'st Jul 2026
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026
04:15pm, Monday, 20'th Jul 2026
DUBLIN, July 20, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close of the
iShares Russell 2000 Value vs. Morningstar Small Cap: Which ETF Suits Your Portfolio Best?
07:40am, Tuesday, 07'th Jul 2026
IWN delivered a 37.4% one-year return but carries higher fees, while ISCV offers a 0.06% expense ratio and stronger dividend yield of 1.9%.
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
10:40am, Monday, 06'th Jul 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Jazz Pharmaceuticals (JAZZ) Price Forecast: Will Breakout Confirm Higher Highs?
05:03pm, Thursday, 02'nd Jul 2026
Jazz Pharmaceuticals is testing a bull flag breakout following a long-term base advance, with confirmation needed above key swing resistance to validate continuation toward new highs.
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Momentum Stock: Should You Buy?
10:52am, Tuesday, 30'th Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks
02:40pm, Tuesday, 23'rd Jun 2026
Zepzelca's failed trial doesn't derail Jazz's growth strategy. First-line adoption is becoming Zepzelca's biggest opportunity.
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies
11:31am, Thursday, 18'th Jun 2026
Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
12:54pm, Wednesday, 17'th Jun 2026
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies.
Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
07:43am, Wednesday, 17'th Jun 2026
Jazz Pharmaceuticals has signed a research collaboration and licensing agreement with Canada's AbCellera to develop T-cell engaging multispecific antibodies for cancer, the companies said on Wed
